Baroldi Joseph 4
4 · IONIS PHARMACEUTICALS INC · Filed Feb 2, 2026
Research Summary
AI-generated summary of this filing
Ionis (IONS) EVP Joseph Baroldi Sells 5,296 Shares
What Happened
Joseph Baroldi, Executive Vice President and Chief Business Officer of Ionis Pharmaceuticals (IONS), had 10,278 performance-based restricted stock units (PRSUs) vest on 2026-01-29 (awarded at $0.00) and sold 5,296 shares in open-market transactions on 2026-01-30 for a weighted average price of $82.96, totaling about $439,364. The vested PRSUs reflect a payout of 167.27% of target for a performance period tied to relative total shareholder return.
Key Details
- Transaction dates: Vesting/award 2026-01-29 (A); open-market sale 2026-01-30 (S). Filing date: 2026-02-02 (filed within standard reporting window).
- Sale price: weighted average $82.96; sales executed at prices ranging $82.95–$82.97 (multiple transactions). Total proceeds ≈ $439,364.
- Award details: PRSUs were for a 2023 grant; Compensation Committee certified performance at 167.27% of target (payout range originally 0%–200%).
- Shares owned after the transactions: Not specified in the excerpt provided.
- No 10b5-1 plan or tax-withholding sale code is disclosed in the provided filing; F2 notes the filer will provide a per-price breakdown on request.
Context
This filing shows a common sequence for executives: performance-based RSUs vested and a portion of shares was sold in the open market. The vesting was performance-driven (relative TSR vs. peers) and the sale generated roughly $439K in proceeds. The filing provides footnote detail on the performance certification and the exact sale price range.
Insider Transaction Report
- Award
Common Stock
[F1]2026-01-29+10,278→ 50,709 total - Sale
Common Stock
[F2]2026-01-30$82.96/sh−5,296$439,364→ 45,413 total
- 4,772(indirect: By Spouse)
Common Stock
Footnotes (2)
- [F1]Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the performance period of the grant to the reporting person reported on January 18, 2023. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 167.27% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 200% based on actual achievement of the goal.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.95 to $82.97 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.